Effect of acid suppression on molecular predictors for esophageal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 2, 2006, Pages 288-293

  Lao Sirieix, Pierre ^a   Roy, Amanda ^b   Worrall, Claire ^a   Vowler, Sarah L ^c   Gardiner, Sue ^a   Fitzgerald, Rebecca C ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CLEAVED CASPASE 3; CYCLOOXYGENASE 2; HISTAMINE H2 RECEPTOR ANTAGONIST; MINICHROMOSOME MAINTENANCE PROTEIN 2; MYC PROTEIN; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CELL PROLIFERATION; DEMEESTER SCORE; DRUG EFFECT; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SCORING SYSTEM; STOMACH ACID; STOMACH BIOPSY; STOMACH PH; UNITED KINGDOM;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CASPASE 3; CASPASES; CELL CYCLE PROTEINS; CYCLOOXYGENASE 2; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GASTRIC ACID; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; PROTON PUMPS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33644786775     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0528     Document Type: Article

References (49)

1. Devesa SS, Blot WJ, Fraumeni JFJ. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
2. Sarr MG, Hamilton SR, Marrone GC, Cameron JL. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux. Am J Surg 1985;149:187-93.
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
4. Winters CJ, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
5. Fass R, Hell RW, Garewal HS, et al. Correlation of oesophageal acid exposure with Barrett's oesophagus length. Gut 2001;48:310-3.
6. Peters FTM, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489-94.
7. O'Riordan JM, Byrne PJ, Ravi N, Keeling PW, Reynolds JV. Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery. Am J Surg 2004;188:27-33.
8. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877-83.
9. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004;180:387-91.
10. Howden CW, Horing CA. Do proton pump inhibitors induce regression of Barrett's oesophagus? A systematic review. Gastroenterology 1997;112:A152.
11. McDonald ML, Trastek VF, Allen MS, Deschamps C, Pairolero PC. Barretts's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996;111:1135-8; discussion 1139-40.
12. Ortiz A, Martinez de Haro LF, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996;83:274-8.
13. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998;93:536-41.
14. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterology 2003;98:2390-4.
15. Ortiz A, Martinez de Haro LF, Parrilla P, Molina J, Bermejo J, Munitiz V. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors. Br J Surg 1999;86:1472-4.
16. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998;93:711-6.
17. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus: an ex vivo proliferation and differentiation model. J Clin Investig 1996;98:2120-7.
18. Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002;122:299-307.
19. Morgan C, Alazawi W, Sirieix P, Freeman N, Coleman N, Fitzgerald RC. Immediate and early gene response to in vitro acid exposure in a Barrett's adenocarcinoma cell line. Gut 2003;52:A44.
20. Chen LQ, Hu CY, Gaboury L, Fera M, Ferraro P, Duranceau AC. Proliferative activity in Barrett's esophagus before and after antireflux surgery. Ann Surg 2001;234:172-80.
21. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 2000;231:303-21.
22. Tselepis C, Morris CD, Wakelin D, et al. Up-regulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003;52:174-80.
23. Kaur BS, Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002;283:G327-34.
24. Buttar NS, Wang KK, Anderson MA, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 2002;94:422-9.
25. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
26. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995;76:1116-9.
27. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002;122:1101-12.
28. Chen X, Li N, Wang S, et al. Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and α-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis 2002;23:2095-102.
29. Li Z, Shimada Y, Kawabe A, et al. Suppression of N- nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis 2001;22:547-51.
30. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64:1561-9.
31. Sirieix PS, O'Donovan M, Brown J, Save V, Coleman N, Fitzgerald RC. Surface Expression of Minichromosome Maintenance Proteins Provides a Novel Method for Detecting Patients at Risk for Developing Adenocarcinoma in Barrett's Esophagus. Clin Cancer Res 2003;9:2560-6.
32. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-21.
33. Maley CC, Galipeau PC, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004;64:7629-33.
34. Pellish LJ, Hermos JA, Eastwood GL. Cell proliferation in three types of Barrett's epithelium. Gut 1980;21:26-31.
35. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992;103:1769-76.
36. Lao-Sirieix P, Brais R, Lovat L, Coleman N, Fitzgerald RC. Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis. Neoplasia 2004;6:751-60.
37. Freeman A, Morris LS, Mills AD, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-32.
38. Richter JE, Bradley LA, DeMeester TR, Wu WC. Normal 24-hr ambulatory esophageal pH values. Influence of study center, pH electrode, age, and gender. Dig Dis Sci 1992;37:849-56.
39. Abdalla SI, Lao-Sirieix P, Novelli MR, Lovat LB, Sanderson IR, Fitzgerald RC. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004;10:4784-92.
40. Yuen MF, Wu PC, Lai VC, Lau JY, Lai CL. Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer 2001;91:106-12.
41. Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, Williams GH. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 2002;50:373-7.
42. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastrooesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004;20:637-43.
43. Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003;17:1237-45.
44. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95:2-8.
45. Gerson LB, Shetler K, Triadafilopoulos G. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus. Dig Liver Dis 2005;37:651-8.
46. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999;117:327-35.
47. Haigh CR, Attwood SE, Thompson DG, et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003;124:615-25.
48. Miller CT, Moy JR, Lin L, et al. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res 2003;9:4819-25.
49. Sarbia M, Tekin U, Zeriouh M, Donner A, Gabbert HE. Expression of the RB protein, allelic imbalance of the RB gene and amplification of the CDK4 gene in metaplasias, dysplasias and carcinomas in Barrett's oesophagus. Anticancer Res 2001;21:387-92.